v3.25.3
Collaborative and Other Relationships - Samsung Bioepis (Details)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2019
product
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Collaborative arrangements and non-collaborative arrangement transactions            
Collaboration profit sharing/(loss reimbursement)   $ 87.2 $ 69.3 $ 220.3 $ 197.3  
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Collaboration profit sharing/(loss reimbursement)   66.5 $ 60.3 $ 171.7 $ 176.8  
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Contingent Commercialized Rights, Number Of Products | product 2          
Expected profit share percentage 45.00%     50.00%    
Impairment of intangible assets (excluding goodwill)           $ 20.2
Estimated additional payments upon achievement of development and commercial milestones           150.0
Collaboration agreement term       5 years    
Option exercise fee       $ 60.0    
Samsung Bioepis | Related Party            
Collaborative arrangements and non-collaborative arrangement transactions            
Accounts receivable   4.8   4.8   7.6
Accounts payable   $ 45.3   $ 45.3   $ 60.8